CytomX Therapeutics Inc’s filing revealed that its Chief Financial Officer Ogden Christopher unloaded Company’s shares for reported $28540.0 on Jun 16 ’25. In the deal valued at $2.69 per share,10,614 shares were sold. As a result of this transaction, Ogden Christopher now holds 226,271 shares worth roughly $0.54 million.
Then, Ogden Christopher sold 1,641 shares, generating $4,841 in total proceeds. Upon selling the shares at $2.95, the Chief Financial Officer now owns 199,385 shares.
Before that, BELVIN MARCIA sold 13,884 shares. CytomX Therapeutics Inc shares valued at $37,334 were divested by the SVP, Chief Scientific Officer at a price of $2.69 per share. As a result of the transaction, BELVIN MARCIA now holds 272,252 shares, worth roughly $0.65 million.
H.C. Wainwright upgraded its CytomX Therapeutics Inc [CTMX] rating to a Buy from a a Neutral in a research note published recently. Piper Sandler also remained covering CTMX and has increased its forecast on May 28, 2024 with a “an Overweight” recommendation from previously “Neutral” rating. Wedbush revised its rating on May 09, 2024. It rated CTMX as “an Outperform” which previously was an “a Neutral”.
Price Performance Review of CTMX
On Tuesday, CytomX Therapeutics Inc [NASDAQ:CTMX] saw its stock fall -3.25% to $2.38. Over the last five days, the stock has lost -11.85%. CytomX Therapeutics Inc shares have risen nearly 131.07% since the year began. Nevertheless, the stocks have risen 63.01% over the past one year. While a 52-week high of $3.10 was reached on 06/13/25, a 52-week low of $0.40 was recorded on 04/07/25.
Levels Of Support And Resistance For CTMX Stock
The 24-hour chart illustrates a support level at 2.30, which if violated will result in even more drops to 2.21. On the upside, there is a resistance level at 2.50. A further resistance level may holdings at 2.61.
